NASDAQ:BWAY Brainsway (BWAY) Stock Price, News & Analysis $15.10 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$15.09 -0.01 (-0.07%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Brainsway Stock (NASDAQ:BWAY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Brainsway alerts:Sign Up Key Stats Today's Range$15.01▼$15.3750-Day Range$12.26▼$17.1752-Week Range$5.01▼$17.35Volume74,754 shsAverage Volume156,342 shsMarket Capitalization$604.60 millionP/E Ratio43.14Dividend YieldN/APrice Target$15.00Consensus RatingModerate Buy Company Overview Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs. The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices. Brainsway has secured regulatory clearances in key markets, including U.S. Food and Drug Administration approvals for treatment-resistant major depressive disorder, obsessive-compulsive disorder, and smoking cessation. In addition to cleared indications, the company is pursuing clinical studies in areas such as migraine and substance use disorders to expand its therapeutic portfolio. Founded in 2003 and headquartered in Jerusalem, Israel, Brainsway operates through subsidiaries and distribution partners across North America, Europe and the Asia-Pacific region. The company maintains a sales and support presence in the United States, including a facility in North Carolina, and collaborates with academic medical centers and independent clinics to facilitate training, research and patient access. Brainsway’s leadership team brings together experts in neuroscience, clinical medicine and medical technology commercialization. The company continues to invest in research collaborations and real-world evidence initiatives aimed at demonstrating the long-term safety, efficacy and health-economic value of its Deep TMS solutions.AI Generated. May Contain Errors. Read More Brainsway Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreBWAY MarketRank™: Brainsway scored higher than 37% of companies evaluated by MarketBeat, and ranked 687th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingModerate Buy Consensus RatingBrainsway has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for Brainsway is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBrainsway has only been the subject of 3 research reports in the past 90 days.Read more about Brainsway's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth50.00% Earnings GrowthEarnings for Brainsway are expected to grow by 50.00% in the coming year, from $0.30 to $0.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Brainsway is 43.14, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Brainsway is 43.14, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.01.Price to Book Value per Share RatioBrainsway has a P/B Ratio of 7.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Brainsway's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.37% of the float of Brainsway has been sold short.Short Interest Ratio / Days to CoverBrainsway has a short interest ratio ("days to cover") of 1.16, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainsway has recently increased by 20.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBrainsway does not currently pay a dividend.Dividend GrowthBrainsway does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Brainsway this week, compared to 3 articles on an average week.Search Interest8 people have searched for BWAY on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows3 people have added Brainsway to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Brainsway insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of Brainsway is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions30.11% of the stock of Brainsway is held by institutions.Read more about Brainsway's insider trading history. Receive BWAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainsway and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BWAY Stock News HeadlinesContrasting Evolus (NASDAQ:EOLS) and Brainsway (NASDAQ:BWAY)May 24 at 3:37 AM | americanbankingnews.comBrainsWay Announces Minority-Stake Investment in Hopemark HealthMay 18, 2026 | globenewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.May 25 at 1:00 AM | Banyan Hill Publishing (Ad)Brainsway (NASDAQ:BWAY) Downgraded by Wall Street Zen to HoldMay 16, 2026 | americanbankingnews.comBrainsWay shares slip despite first-quarter earnings beat and strong growth (BWAY)May 14, 2026 | finance.yahoo.comBrainsway (NASDAQ:BWAY) Cut to "Hold" at Zacks ResearchMay 14, 2026 | americanbankingnews.comBrainsWay Ltd. (BWAY) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comBrainsWay Reports First Quarter 2026 Financial Results and Operational HighlightsMay 13, 2026 | globenewswire.comSee More Headlines BWAY Stock Analysis - Frequently Asked Questions How have BWAY shares performed this year? Brainsway's stock was trading at $9.51 at the beginning of the year. Since then, BWAY shares have increased by 58.8% and is now trading at $15.10. How were Brainsway's earnings last quarter? Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) issued its quarterly earnings results on Wednesday, May, 13th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.07. The business had revenue of $15.53 million for the quarter, compared to the consensus estimate of $14.63 million. Brainsway had a net margin of 15.68% and a trailing twelve-month return on equity of 12.28%. Read the conference call transcript. When did Brainsway's stock split? Shares of Brainsway split on Tuesday, March 3rd 2026.A 2-1 split was announced. The newly created shares were payable to shareholders after the market closes on Monday, March 2nd 2026. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. When did Brainsway IPO? Brainsway (BWAY) raised $28 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.00 per share. Cantor served as the underwriter for the IPO. Who are Brainsway's major shareholders? Brainsway's top institutional investors include Masters Capital Management LLC (4.12%), Renaissance Technologies LLC (1.29%), Y.D. More Investments Ltd (0.68%) and Sei Investments Co. (0.57%). How do I buy shares of Brainsway? Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Brainsway own? Based on aggregate information from My MarketBeat watchlists, some other companies that Brainsway investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Novo Nordisk A/S (NVO) and AppLovin (APP). Company Calendar Last Earnings5/13/2026Today5/25/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BWAY's financial health is in the Green zone, according to TradeSmith. BWAY has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:BWAY CIK1505065 Webwww.brainsway.com Phone(722) 582-4030FaxN/AEmployees120Year Founded2003Price Target and Rating Average Price Target for Brainsway$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside-0.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.35 Trailing P/E Ratio43.14 Forward P/E Ratio50.33 P/E GrowthN/ANet Income$7.57 million Net Margins15.68% Pretax Margin15.75% Return on Equity12.28% Return on Assets7.75% Debt Debt-to-Equity RatioN/A Current Ratio3.34 Quick Ratio3.04 Sales & Book Value Annual Sales$52.22 million Price / Sales11.58 Cash Flow$0.23 per share Price / Cash Flow64.49 Book Value$1.89 per share Price / Book7.99Miscellaneous Outstanding Shares40,040,000Free Float32,431,000Market Cap$604.60 million OptionableNot Optionable Beta1.23 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:BWAY) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainsway Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainsway With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
